Here's What Key Metrics Tell Us About ResMed (RMD) Q4 Earnings

ResMed (RMD) reported $1.35 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 10.2%. EPS of $2.55 for the same period compares to $2.08 a year ago.The reported revenue represents a surprise of +1.87% over the Zacks Consensus Estimate of $1.32 billion. With the consensus EPS estimate being $2.46, the EPS surprise was +3.66%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how ResMed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:U.S., Canada, and Latin America- Devices: $432.8 million compared to the $435.08 million average estimate based on five analysts. The reported number represents a change of +6.6% year over year.U.S., Canada, and Latin America- Masks and other: $359.2 million compared to the $349.01 million average estimate based on five analysts. The reported number represents a change of +11.8% year over year.Combined Europe, Asia, and other markets- Total: $389 million versus $371.49 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +13.1% change.Combined Europe, Asia, and other markets- Devices: $261.1 million versus the five-analyst average estimate of $246.43 million. The reported number represents a year-over-year change of +14.1%.Combined Europe, Asia, and other markets- Masks and other: $127.9 million versus $125.06 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +11.2% change.U.S., Canada, and Latin America- Total: $791.9 million compared to the $784.09 million average estimate based on five analysts. The reported number represents a change of +8.9% year over year.Global revenue- Total Sleep and Breathing Health: $1.18 billion versus $1.16 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.Global revenue- Residential Care Software: $167 million compared to the $166.5 million average estimate based on six analysts. The reported number represents a change of +9.9% year over year.Global revenue- Total Devices: $693.9 million versus the five-analyst average estimate of $681.51 million. The reported number represents a year-over-year change of +9.3%.Global revenue- Total Masks and other: $487.1 million versus $474.07 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +11.7% change.View all Key Company Metrics for ResMed here>>>Shares of ResMed have returned +8.4% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.One Big Gain, Every Trading DayTo help you take full advantage of this market, you’re invited to access every stock recommendation in all our private portfolios - for just $1.Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That’s about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ResMed Inc. (RMD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks